BOOK NOW!

Proventa International's 5th Annual

ONCOLOGY

STRATEGY MEETING WEST COAST USA 2023

10th May 2023, Wednesday | Hard Rock Hotel San Diego

Exploring Promising Areas in Oncology Research Aimed to Expand Our Knowledge Base, Address Unmet Medical Needs and Improve Overall Clinical Success

NEW FOR 2023:
Investment, Private Equity & Venture Capital Partnerships

Featuring Industry Leaders and Decision Makers:

Nathaniel Wang
Chief Executive Officer and Co-Founder
Replicate Biosciences

Oscar Segurado
Chief Medical Officer
ASC Therapeutics

Matthew Spear
Chief Development Officer / Chief Medical Officer
Denovo Biopharma

Boris Minev
President, Medical & Scientific Affairs
Calidi Biotherapeutics

Will Robberts
President
LIPAC Oncology

Karin Zeh
Vice President, Program and Portfolio Management
Bristol Myers Squibb

Joanne Sloan Lancaster
Vice President, Program Team Leadership
NGM Bio

24 ROUNDTABLE DISCUSSIONS

6 TRACKS

2 KEYNOTE PRESENTATIONS

1 LOCATION

What Makes Our Strategy Meetings So Unique?

Proud to Partner with:

BasePair Biotechnologies, Inc. | CERTIS ONCOLOGY INTELLIGENCE | LARVOL | current health From BEST BUY Health | median

Scan to register

Proventa International's Strategy Meetings are a completely unique experience.

ONCOLOGY

STRATEGY MEETING WEST COAST USA 2023

10th May 2023, Wednesday | Hard Rock Hotel San Diego

We're committed to delivering long-term value across our extensive life science network. Through our carefully crafted meetings, collaborative experiences and services Proventa International can offer you the perfect opportunity to meet your business goals, whatever they may be.

Our Vision

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

Our Mission

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

Our Unique Meeting Format

ROUNDTABLE DISCUSSIONS

These interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

PERSONALISED AGENDA

Each delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent is focused and well-utilised.

INNOVATIVE SOLUTIONS

The most effective and time efficient way to assess potential partners at a strategic level. Identify key solution providers that can take your business to the next level and we will help arrange private meetings so you can connect.

STRATEGIC NETWORKING

Strategic networking opportunities form a key benefit of the meeting. Our proven format for building and strengthening alliances to make lasting connections that benefit you.

Seniority of Attendees

- Director Level
- Department Head
- Other
- Team Lead
- Academia
- Scientist
- C-Level
- President / VP
- Manager



Oncology

- Oncology
- Biomarker Discovery
- Translational Medicine
- Companion Diagnostics
- Antibody Drug Discovery
- Genomics
- R&D
- Drug Discovery
- Clinical Development
- Clinical Operations
- Precision Medicine

Meet Investors

- Venture Capital
- Private Equity
- Large Pharma/Biotech
- Corporate Venture Capital
- Institutional
- High Net Worth
- Family Office/Private Wealth
- Government Organisation/ Sovereign Wealth Fund
- Angel

Facilitator Faculty

ONCOLOGY
STRATEGY MEETING WEST COAST USA 2023
10th May 2023, Wednesday Hard Rock Hotel San Diego

Ana Krtolica
Senior Vice President,
Preclinical Development
Oryn Therapeutics

Anna Vardanyan
Vice President,
Business Development
Inmagene Biopharma

Oscar Segurado
Chief Medical Officer
ASC Therapeutics

Boris Minev
President, Medical &
Scientific Affairs
Calidi Biotherapeutics

Charles Theuer
Chief Executive Officer
TRACON Pharmaceuticals

Gajanan Bhat
Senior Vice President,
Clinical Sciences
Spectrum Pharmaceuticals

Gregory Opiteck
Chief Medical Officer
Allogene Therapeutics

Jack Florio
Managing Director
Weild & Co

Jason B. Litten
Chief Medical Offficer
Chimeric Therapeutics

Joanne Sloan Lancaster
Vice President,
Program Team
Leadership
NGM Bio

Joe Stalder
Executive Director
Project Management
Mirati Therapeutics

Karin Zeh
Vice President,
Program and Portfolio
Management
Bristol Myers Squibb

Majid Ghoddusi
Executive Director,
Clinical Biomarkers
Janux Therapeutics

Matthew Spear
Chief Development Officer /
Chief Medical Officer
Denovo Biopharma

Hui Zhou
Chief Scientific Officer
Phanes Therapeutics, Inc.

Nathaniel Wang
Chief Executive Officer
and Co-Founder
Replicate Biosciences

Ron Shazer
Vice President of CIlnical
Development
Mirati Therapeutics

Stan Jin
Co-founder and
Chief Executive Officer
Molecular Axiom

Will Robberts
President
LIPAC Oncology

How Has Our **STRATEGY MEETINGS** Benefit The Life Science Industry

An excellent opportunity to promote engagement and cooperation across various challenges. It is indeed very insightful to observe and learn from a wealth of expertise on a range of scientific accomplishments. Kudos to all in the planning and production of these meetings on a well curated remote platform."

Gurdyal Kalsi - *CMO*, **Asklepion Pharmaceuticals**

Great meeting, very informative. And your team support is supreme! I got my meeting agenda, reminders, etc. I had perfect attendance! "

Alejandro Ricart -
VP, Oncology Clinical Development, **TG Therapeutics**

2023 Sponsors

CO-HOST SPONSORS

Base Pair Biotechnologies is based just 10 miles south of the Houston, Texas Medical Center. Our team of 11 scientists has a combined 50+ person-years of experience in developing aptamers. Base Pair owns the sole worldwide rights to patents for multiplexed aptamer discovery. We have the capability to select aptamers to up to 30 protein, peptide, or small molecule targets in true competitive, multiplexed fashion. The resulting aptamers are therefore more specific for their particular targets. Using this technology, we have completed contracts from the National Cancer Institute, the CDC, and many large pharma and biotech firms and can serve as an excellent partner to help achieve your drug discovery and validation needs.

Certis Oncology is a precision oncology and translational science company focused on combining functional assays and artificial intelligence to advance precision medicine. Our product is "Oncology Intelligence™"—highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. We partner with oncology therapeutics developers to help close the problematic translation gap between preclinical studies and clinical trials. Through more clinically relevant and well-characterized tumor models, advanced imaging, focal and whole-body irradiation, immuno-oncology expertise, and thoughtfully designed studies, Certis brings greater certainty to go/no-go development decisions.

LARVOL supports the data and intelligence needs of the pharmaceutical and biotech industry with expert curated information. Their products include competitive intelligence, KOL monitoring, and social listening tools along with predictive cancer biomarker and clinical trial databases. With a growing focus on the oncology space, LARVOL curates data from over 25,000 sources and distills the most relevant information into concise reports and easy-to-use platforms that provide real-time insights and timesaving analysis to pharma teams.

KEY OPINION LEADER

current health From BEST BUY Health

median

Global Sponsorship Opportunities

Proventa's end-to-end consulting division gather real-time business intelligence on the industry's **needs, challenges, budgets** and **investment areas**. We combine this information with your specific needs to enhance your business development strategy. With the wealth of intel we provide, Proventa guarantees tangible results for your business within twelve months of the event.

For Sponsorship Opportunites please contact:
SPONSORSHIP TEAM: info@proventainternational.com | +44 (0)20 3314 0100

Agenda at a Glance

ONCOLOGY
STRATEGY MEETING WEST COAST USA 2023
10th May 2023, Wednesday | Hard Rock Hotel San Diego

TIME (PT)	TRACK 1 IMMUNO-ONCOLOGY	TRACK 2 TARGETED THERAPY	TRACK 3 PRECISION MEDICINE/ COMPANION DIAGNOSTICS	TRACK 4 BIOMARKER DISCOVERY	TRACK 5 CLINICAL RESEARCH & DEVELOPMENT	New TRACK 6 INVESTMENT, PRIVATE EQUITY & VENTURE CAPITAL PARTNERSHIPS
ROOM ►	Encore 1	Encore 2	Encore 3	Imagine 1	Imagine 1	Watchtower
08:00 - 08:30	BREAKFAST & REGISTRATION					
08:30 - 09:00	OPENING KEYNOTE PRESENTATION Allogeneic Stem Cell-Based Platforms to Potentiate and Deliver Oncolytic Virus Therapies PRESENTER: Boris Minev, *President, Medical & Scientific Affairs*, Calidi Biotherapeutics					
09:00 - 10:00	**Reprogramming the tumor microenvironment (TME) to improve immunotherapy outcomes** Boris Minev, *President, Medical & Scientific Affairs*, Calidi Biotherapeutics	**Improving cancer combination therapy by timing drug administration** Oscar Segurado, *Chief Medical Officer*, ASC Therapeutics	**Beyond genomics – what is the potential, and what are barriers to multi-omics profiling** Ana Krtolica, *Senior Vice President, Preclinical Development*, Oryn Therapeutics	**Employing the circulations of tumor DNA (ctDNA) as a biomarker or an early endpoint in early-stage solid tumor clinical trials** Majid Ghoddusi, *Executive Director, Clinical Biomarkers*, Janux Therapeutics	**Incorporating real-world-evidence in the clinical development process for faster submissions and accelerated approvals** Gajanan Bhat, *Senior Vice President, Clinical Sciences*, Spectrum Pharmaceuticals	**Creative solutions for funding early stage oncology innovation** Will Robberts, *President*, LIPAC Oncology
10:00 - 10:10	REFRESHMENT BREAK					
10:10 - 10:30	NETWORKING / 1-1 MEETINGS					
10:30 - 10:50	NETWORKING / 1-1 MEETINGS					
10:50 - 11:10	NETWORKING / 1-1 MEETINGS					
11:10 - 12:10	**Latest Innovations in Immuno-oncology to unleash better and more effective immunotherapy options** Nathaniel Wang, *Chief Executive Officer and Co-Founder*, Replicate Biosciences	**Addressing operational challenges of developing targeted therapies to treat increasingly precise oncologic mutations** Joe Stalder, *Executive Director Project Management*, Mirati Therapeutics Ron Shazer, *Vice President of CIlnical Development*, Mirati Therapeutics		**Examining how integrated approaches to cancer biomarker discovery may reveal how predictive gene signatures are of cancer progression** Karin Zeh, *Vice President, Program and Portfolio Management*, Bristol Myers Squibb	**Evaluating the benefits of in-house clinical development and operations** Charles Theuer, *Chief Executive Officer*, TRACON Pharmaceuticals	**Best practices and success factors to raising funds and building an innovative biotech company. Which assets and technologies investors will be looking for in your intellectual property portfolio** Anna Vardanyan, *Vice President, Business Development*, Inmagene Biopharma
12:10 - 13:10	NETWORKING LUNCH					
13:10 - 13:40	AFTERNOON KEYNOTE PRESENTATION The Design, Construction, and Manufacture of Bispecific Antibodies in Oncology PRESENTER: Hui Zhou, *Chief Scientific Officer*, Phanes Therapeutics, Inc					
13:40 - 14:40	**Advancing Cell Therapies for Solid Tumor Patients** Jason B. Litten, *Chief Medical Offficer*, Chimeric Therapeutics	**Gene Therapy Targeting with Replicating Vector** Matthew Spear, *Chief Development Officer / Chief Medical Officer*, Denovo Biopharma	**Trends, challenges, controversies, and cost-considerations of precision oncology approaches and targeted therapies** Karin Zeh, *Vice President, Program and Portfolio Management*, Bristol Myers Squibb	**Applications of biomarkers to enhance response to immuno-oncology therapeutics** Hui Zhou, *Chief Scientific Officer*, Phanes Therapeutics, Inc.	**Challenges and opportunities in Oncology Clinical development** Joanne Sloan Lancaster, *Vice President, Program Team Leadership*, NGM Bio	**An insight into the investor mindset: How to identify, analyse and mitigate risk in a competitive market.** Stan Jin, *Co-founder and Chief Executive Officer*, Molecular Axiom Jack Florio, *Managing Director*, Weild & Co
14:40 - 14:50	REFRESHMENT BREAK					
14:50 - 15:10	NETWORKING / 1-1 MEETINGS					
15:10 - 15:30	NETWORKING / 1-1 MEETINGS					
15:30 - 15:50	NETWORKING / 1-1 MEETINGS					
15:50 - 16:20	PANEL DISCUSSION Role of Biomarkers in Personalizing Cell Therapy for Oncology Patients PRESENTER: Gregory Opiteck, *Chief Medical Officer*, Allogene Therapeutics					
16:20 - 17:20	DRINKS & CANAPES RECEPTION					

Event Day | Keynote Presentations

A great way to open the roundtable discussions is through a timely presentation from a top-tier biotech/pharmaceutical company. Listen as we hear this 30-minute exposition on this meeting's pressing topic.

08:30 - 09:00 PT **OPENING KEYNOTE PRESENTATION**

Allogeneic Stem Cell-Based Platforms to Potentiate and Deliver Oncolytic Virus Therapies

Oncolytic virotherapy utilizes viruses that preferentially infect and replicate within cancer cells, resulting in both direct lysis of the tumor cells as well as activation of an anti-tumor immune response, while leaving healthy cells unharmed.

A major obstacle to this approach has been the rapid oncolytic virus elimination by patient's immune system. Therefore, the therapeutic potential of the oncolytic virotherapy is severely restricted.
The novel Calidi's platform leverages allogeneic stem cells, combined with an oncolytic virus payload, which prevents the viral elimination by the patient's immune system, and facilitates initial viral amplification and expansion at the tumor sites.

Calidi's platforms incorporate three important elements:

- Ability to protect oncolytic viruses from inactivation by complement, blocking antibodies and innate immune cells.
- Ability to support oncolytic viral amplification in the stem cells.
- Ability to modify tumor microenvironment by inducing transient immune suppression to allow effective tumor cell targeting and viral amplification at the tumor sites for an extended period.

Importantly, Calidi's final product contains not only stem cells loaded with viral particles, but also immune modulatory cytokines produced by the stem cells as well as virally encoded proteins. Therefore, the tumor microenvironment (TME) is modified immediately upon intratumoral injection to support effective viral amplification and oncolysis.

Boris Minev
President, Medical & Scientific Affairs
Calidi Biotherapeutics

ABOUT THE SPEAKER
Dr. Boris Minev is a highly accomplished physician-scientist with extensive industrial and academic experience in Immuno-Oncology, oncolytic viruses and stem cell biology and applications. He has a significant track record in tumor immunology and cancer vaccine development. Prior to joining Calidi Biotherapeutics, Dr. Minev was the Director of Immunotherapy and Translational Oncology at Genelux Corporation, where he was directing translational projects on oncolytic virotherapy, immunotherapy and nanotechnology. Dr. Minev is a member of the Scientific and Clinical Advisory Boards of several biotechnology companies, and has been an advisor for Amgen, Johnson & Johnson, Geron Corporation, McKinsey Consulting and Thomson Current Drugs, among others.

13:10 - 13:40 PT **AFTERNOON KEYNOTE PRESENTATION**

The Design, Construction, and Manufacture of Bispecific Antibodies in Oncology

Hui Zhou
Chief Scientific Officer
Phanes Therapeutics, Inc.

ABOUT THE SPEAKER
Dr. Hui Zou is the Chief Scientific Officer (CSO) of Phanes Therapeutics. He is an experienced and accomplished oncologist in both academia of biological research and industry of drug development. Before joining the industry, Hui was a tenured Associate Professor at UT Southwestern Medical Center. He joined the industry to translate his scientific expertise into biomedical drug discovery and development. Before joining Phanes, he was the CSO of Gan&Lee Pharmaceuticals. Dr. Zou holds a PhD degree of genetics and development from Columbia University. He was awarded fellow of Jane Coffin Childs Memorial Fund for Medical Research, American Cancer Society Research Scholar, and Kenneth G. and Elaine A. Langone Scholar of Damon Runyon Cancer Research Foundation.

15:50 - 16:20 PT **PANEL DISCUSSION**

Role of Biomarkers in Personalizing Cell Therapy for Oncology Patients

Gregory Opiteck
Chief Medical Officer
Allogene Therapeutics

ABOUT THE SPEAKER

Speaker TBC

Event Day

TRACK 1

Immuno-Oncology

Immuno-Oncology (IO) has been successful in the targeted treatment of cancer, but not all patients benefit from effective anticancer Immunotherapy because they fail to achieve complete responses, suffer frequent relapses, or develop potentially life-threatening toxicities. As time progresses, these challenges remain in understanding why some tumor types are refractive to immunotherapy and how to better predict patient responses to treatment. This track will convene experts in immuno-oncology to discuss the latest research in the field and how we can optimize treatment.

08:00 - 08:30 PT BREAKFAST & REGISTRATION

08:30 - 09:00 PT OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 PT ROUNDTABLE 1

Reprogramming the tumor microenvironment (TME) to improve immunotherapy outcomes

- Analysis of the various facets of the TME and their role in the resistance mechanisms to immunotherapy
- New ways to overcome the resistance to checkpoint inhibitors-based immunotherapies
- Targeting tumor vasculature to improve immunotherapy outcomes
- Converting immunologically “cold” tumors into “hot” tumors utilizing oncolytic viruses
- Reprogramming myeloid cells and regulatory T cells to induce anti-tumor immunity

Boris Minev
President, Medical & Scientific Affairs
Calidi Biotherapeutics

ABOUT THE SPEAKER
Dr. Boris Minev is a highly accomplished physician-scientist with extensive industrial and academic experience in Immuno-Oncology, oncolytic viruses and stem cell biology and applications. He has a significant track record in tumor immunology and cancer vaccine development. Prior to joining Calidi Biotherapeutics, Dr. Minev was the Director of Immunotherapy and Translational Oncology at Genelux Corporation, where he was directing translational projects on oncolytic virotherapy, immunotherapy and nanotechnology. Dr. Minev is a member of the Scientific and Clinical Advisory Boards of several biotechnology companies, and has been an advisor for Amgen, Johnson & Johnson, Geron Corporation, McKinsey Consulting and Thomson Current Drugs, among others.

10:00 - 11:10 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

11:10 - 12:10 PT ROUNDTABLE 2

Latest Innovations in Immuno-oncology to unleash better and more effective immunotherapy options

- What is the future role of immuno-oncology in targeting acquired resistance mutations as an alternative to small molecule approaches
- How should the field think about the integration of biomarkers into the design of trials for future IO agents
- Beyond checkpoint inhibitors, what are some additional combinations for IO that the field should be considering moving forward

Nathaniel Wang
Chief Executive Officer and Co-Founder
Replicate Biosciences

ABOUT THE SPEAKER
Dr. Nathaniel Wang is the Chief Executive Officer and Cofounder at Replicate Bioscience. He has 15+ years of leadership experience in immunology and drug development. He is a pioneer in synthetic, self-replicating RNA technologies and their delivery and is also a recognized expert in the fields of immuno-oncology and infectious disease. Prior to Replicate Dr. Wang headed RNA Medicines business unit at Synthetic Genomics, which was acquired by Janssen in 2019. At Janssen, he led teams developing srRNA compounds in multiple therapeutic areas. He received a Ph.D. in Immunology from The Scripps Research Institute and a B.A. in Immunology from UC Berkeley.

12:10 - 13:10 PT NETWORKING LUNCH

13:10 - 13:40 PT AFTERNOON KEYNOTE PRESENTATION
See Page 6

13:40 - 14:40 PT ROUNDTABLE 3

Advancing Cell Therapies for Solid Tumor Patients

- Genetically modified T-cells are curative for some patients with B-cell malignancies
- How do we deliver comparable outcomes using cell therapies in patients with solid tumors?
- Emerging cell therapy programs in solid tumor indications provide great hope for the future

Jason B. Litten
Chief Medical Offficer
Chimeric Therapeutics

ABOUT THE SPEAKER
Jason B. Litten MD is the Chief Medical Officer at Chimeric Therapeutics and an expert in cellular therapeutics and clinical oncology. Prior to Chimeric, Jason served as the Chief Medical Officer at Artiva Biotherapeutics. Jason holds a BS from Cornell University and MD from Emory University. He completed a Residency in General Pediatrics at University of Miami and a Clinical Fellowship in Pediatric Hematology & Oncology at UT Southwestern. Since leaving academic medicine over 15 years ago, Dr Litten has been dedicated to developing new medicines for cancer patients in the biotech and pharmaceutical field.

14:40 -15:50 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

15:50 - 16:20 PT PANEL DISCUSSION
See Page 6

16:20 -17:20 PT DRINKS & CANAPES RECEPTION

Event Day

TRACK 2

Targeted Therapy

Targeted therapy is a type of cancer treatment that targets specific genes and proteins that help cancer cells survive and grow. Healthcare providers test for the genetic changes responsible for helping cancer cells grow and survive and identify specific treatments to kill those cells or keep them from growing. This helps them provide treatment for cancer cells without hurting healthy cells. Healthcare providers sometimes use targeted therapy as the front line or initial treatment. They may also combine targeted therapy with other treatments.

08:00 - 08:30 PT **BREAKFAST & REGISTRATION**

08:30 - 09:00 PT **OPENING KEYNOTE PRESENTATION**
See Page 6

09:00 - 10:00 PT **ROUNDTABLE 1**

Improving cancer combination therapy by timing drug administration

- How do we predict the likelihood various combinations of various therapeutic modalities?
- How do we determine the staging of regimens and order of administration?
- Does chemotherapy and radiation have a place in combination with immunotherapy specifically ICI?
- Is the rigorous and thorough monitoring of microenvironment tumors markers play a critical role?

Oscar Segurado
Chief Medical Officer
ASC Therapeutics

ABOUT THE SPEAKER

Dr. Maida is currently Chief Clinical Officer – Translational Medicine for Oncotelic, Inc. focused on the immunotherapy of cancer and infectious disease. Formerly he was Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc., a cancer vaccine company focused on therapy of patients with glioblastoma multiforme and prostate cancer. He is responsible for the oversight of the clinical and scientific operations of Oncotelic Therapeutics, Inc. Dr. Maida was formerly Vice President of Clinical Research and General Manager, Oncology, World-wide for PharmaNet, Inc. Prior to coming to Pharmanet Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street, in the clinical development of therapeutic products and product/company acquisitions.

10:00 - 11:10 PT **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

11:10 - 12:10 PT **ROUNDTABLE 2**

Addressing operational challenges of developing targeted therapies to treat increasingly precise oncologic mutations

- Finding patients who are eligible for clinical trials becomes more difficult as targeted oncogenic drivers become more specific and rare
- Testing patients for novel biomarkers is more difficult because assays are not widely used in practice
- Defining the treatment algorithm is more complicated for patients that have multiple mutations (eg, EGFR, RAF, KRAS, PRMT5)

Joe Stalder
Executive Director
Project Management
Mirati Therapeutics

Ron Shazer
Vice President of
CIlnical Development
Mirati Therapeutics

ABOUT THE SPEAKERS

Joe Stalder is an Executive Director of Project Management at Mirati Therapeutics in San Diego, CA, co-founder of Groundswell Pharma Consulting, and editor of the book "Project Management for Drug Developers". Joe has over 10 years of project management experience in pharmaceutical development in large and small companies. His experience includes Project Management department head, PMO head, and Lead Project Manager on several early- and late-stage development assets in oncology, infectious disease, cardiology, metabolism, and pulmonology. Joe is also a regular speaker at biopharma PPM conferences and is involved in biopharma PPM community organizations including PIPMG and BiopharmaPM.

12:10 - 13:10 PT **NETWORKING LUNCH**

13:10 - 13:40 PT **AFTERNOON KEYNOTE PRESENTATION**
See Page 6

13:40 - 14:40 PT **ROUNDTABLE 3**

Gene Therapy Targeting with Replicating Vector

- Background of gene therapy in oncology
- Vector and transgene
- Clinical trials
- Predictive biomarkers

Matthew Spear
Chief Development Officer / Chief Medical Officer
Denovo Biopharma

ABOUT THE SPEAKER

Dr. Spear has been working in oncology and gene therapy research and development for over 30 years. He received a B.A. degree from Johns Hopkins University and an M.D. degree from Stanford University. Post-graduate training was in the Massachusetts General Hospital / Harvard University program. He has served as an Associate Professor on the faculty of the USC Keck School of Medicine, and the UCSD Medical School / UCSD Cancer Center where he managed a clinical practice, drug discovery/gene therapy research, and clinical trial programs for cancer. Dr. Spear led multiple oncology clinical development programs at Pfizer.

14:40 -15:50 PT **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

15:50 - 16:20 PT **PANEL DISCUSSION**
See Page 6

16:20 -17:20 PT **DRINKS & CANAPES RECEPTION**

Event Day

TRACK 3

Precision Medicine / Companion Diagnostics

Precision medicine has rapidly altered the oncology diagnostic and treatment spectrum by allowing tailored treatment strategies to precisely target the molecular alteration underlying individual patients' disease. With genomic-data sequencing new disease pathways are being discovered, new therapeutic targets are being revealed and ideal treatments populations are being identified which shall be discussed further in this track.

08:00 - 08:30 PT BREAKFAST & REGISTRATION

08:30 - 09:00 PT OPENING KEYNOTE PRESENTATION
See Page 6

09:00 - 10:00 PT ROUNDTABLE 1

Beyond genomics – what is the potential, and what are barriers to multi-omics profiling

- What multi-omics approaches are you considering/have you used?
- What do you expect/actionable data have you gained using multi-omics approaches?
- Major hurdles in implementing multi-omics approaches in clinical trials

Ana Krtolica
Senior Vice President, Preclinical Development
Oryn Therapeutics

ABOUT THE SPEAKER
Ana completed PhD at University of Rochester. As a postdoc and then, scientist at LBNL and UCSF she explored the influence of microenvironment on carcinogenesis and stem cell phenotype. Ana co-founded and led StemLifeLine, a startup focusing on cell therapy and development of the cancer drug discovery platform. After joining Omniox, Ana developed programs in oncology, ischemic stroke and critical care bringing its technology from early discovery to clinic. She currently leads translational and new indication efforts at Retrotope. Ana received >$5M in grants and serves on NIH Review Boards. She authored multiple patent applications and published >30 research papers.

10:00 - 11:10 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

12:10 - 13:10 PT NETWORKING LUNCH

13:10 - 13:40 PT AFTERNOON KEYNOTE PRESENTATION
See Page 6

13:40 - 14:40 PT ROUNDTABLE 3A

Trends, challenges, controversies, and cost-considerations of precision oncology approaches and targeted therapies

- Many targeted therapies address subpopulations in larger indication, best approaches to identify the right patient?
- Is diagnostic testing too expensive and are new approaches on the horizon to address this?
- What are the regulatory challenges precision medicine is facing now and in the future?
- How will AI impact precision medicine?

Karin Zeh
Vice President, Program and Alliance Management
Genesis Therapeutics

ABOUT THE SPEAKER
Dr. Karin Zeh has 25 years of R&D leadership experience focusing on rare diseases and unmet need indications. Most recently Dr. Zeh was employed at Turning Point Therapeutics (a wholly owned subsidiary of Bristol Myers Squibb) as VP of Program and Portfolio Management and served as Program Team Lead for multiple programs. Dr. Zeh began her career in industry as a research scientist but since gained extensive expertise in building and leading program teams and the program management function working with innovative biotechnology companies at all stages of development. Dr. Zeh received her PhD from the University of Heidelberg, Germany and conducted post-graduate work at the Sanford-Prebys Burnham Institute in La Jolla, California.

14:40 -15:50 PT REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS

15:50 - 16:20 PT PANEL DISCUSSION
See Page 6

16:20 -17:20 PT DRINKS & CANAPES RECEPTION

Event Day

TRACK 4

Biomarker Discovery

A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. It may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. While some cancer biomarkers can be used to predict how aggressively your cancer will grow, it is useful to understand the assessment of prognosis, which is deemed as the most promising use of biomarkers today that can help identify which therapies a patient's cancer may or may not respond to.

08:00 - 08:30 PT **BREAKFAST & REGISTRATION**

08:30 - 09:00 PT **OPENING KEYNOTE PRESENTATION**
See Page 6

09:00 - 10:00 PT **ROUNDTABLE 1**

Employing the circulations of tumor DNA (ctDNA) as a biomarker or an early endpoint in early-stage solid tumor clinical trials

- Current applications of ctDNA in solid tumor treatments
- Most promising areas of ctDNA's upcoming utilities in drug development
- How technology improvements could impact the utility of ctDNA

Majid Ghoddusi
Executive Director, Clinical Biomarkers
Janux Therapeutics

ABOUT THE SPEAKER

Dr. Ghoddusi has over 15 years of experience in some of the most challenging areas of oncology with focus on biomarkers in clinical development. Dr Ghoddusi has broad and overarching insights into unmet therapeutic areas with expertise in translational sciences and clinical biomarker development which allows him to provide unique perspective on how to propel therapeutic projects from discovery to approval. Trained as a translational pathologist he has held impactful positions at large pharmaceutical and small biotech companies including Novartis, Celgene, Juno Therapeutics, Five Prime, Poseida Therapeutics. His current role at Janux Therapeutics as Executive Director is to plan and execute wholesome clinical biomarkers strategy in support of Janux T-cell engagers pipeline.

10:00 - 11:10 PT **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

11:10 - 12:10 PT **ROUNDTABLE 2**

Examining how integrated approaches to cancer biomarker discovery may reveal how predictive gene signatures are of cancer progression

- Impacts of predictive gene signature on drug development
- Review new technology advancements and applications in biomarker discovery and development
- Showcase successful drug launches enabled by predictive biomarkers
- Forward looking into the involving regulatory landscape

Karin Zeh
Vice President, Program and Alliance Management
Genesis Therapeutics

ABOUT THE SPEAKER

See Page 9

12:10 - 13:10 PT **NETWORKING LUNCH**

13:10 - 13:40 PT **AFTERNOON KEYNOTE PRESENTATION**
See Page 6

13:40 - 14:40 PT **ROUNDTABLE 3**

Applications of biomarkers to enhance response to immuno-oncology therapeutics

- Use of biomarker expression levels on solid tumors to select target populations
- Determination of the minimal target expression level required for significant response to therapeutics
- Considerations of crosstalk of different pathways and impact on biomarkers under circumstances of combination therapy

Hui Zhou
Chief Scientific Officer
Phanes Therapeutics, Inc.

ABOUT THE SPEAKER

Dr. Hui Zou is the Chief Scientific Officer (CSO) of Phanes Therapeutics. He is an experienced and accomplished oncologist in both academia of biological research and industry of drug development. Before joining the industry, Hui was a tenured Associate Professor at UT Southwestern Medical Center. He joined the industry to translate his scientific expertise into biomedical drug discovery and development. Before joining Phanes, he was the CSO of Gan&Lee Pharmaceuticals. Dr. Zou holds a PhD degree of genetics and development from Columbia University. He was awarded fellow of Jane Coffin Childs Memorial Fund for Medical Research, American Cancer Society Research Scholar, and Kenneth G. and Elaine A. Langone Scholar of Damon Runyon Cancer Research Foundation.

14:40 -15:50 PT **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

15:50 - 16:20 PT **PANEL DISCUSSION**
See Page 6

16:20 -17:20 PT **DRINKS & CANAPES RECEPTION**

Event Day

TRACK 5

Clinical Research & Development

As tumor definitions become more granular and treatments become more specific, the velocity and variety of data is also accelerating in clinical trials, making integration and standardization more complex. Therefore, in order to successfully convert innovative concepts into viable and widely available treatment alternatives for cancer patients, clinical and translational research must likewise adapt to the continually changing environment.

08:00 - 08:30 PT **BREAKFAST & REGISTRATION**

08:30 - 09:00 PT **OPENING KEYNOTE PRESENTATION**
See Page 6

09:00 - 10:00 PT **ROUNDTABLE 1**

Incorporating real-world-evidence in the clinical development process for faster submissions and accelerated approvals

- Real-world data use in rare and ultra rare diseases – how it can provide information on the treatment effect
- Provide insights into clinical trial design
- Can it help in developing a synthetic control arm?

Gajanan Bhat
Vice President Clinical Sciences
Spectrum Pharmaceuticals

ABOUT THE SPEAKER
Dr. Gajanan Bhat is currently the Vice President of Clinical and Data Science at Spectrum Pharmaceuticals, Irvine, CA. Gajanan is a clinical research, development and analytics executive with over 20 years of experience in drugs, biologics, device and imaging diagnostic agent development in multiple pharmaceutical companies. He has led global clinical programs and organization for clinical development and regulatory submissions. Gajanan is a result-oriented team leader and innovative thinker who provides directions to team both scientifically and organizationally. Gajanan is also a past president and the current Chair of regional chapter of the American Statistical Association.

10:00 - 11:10 PT **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

11:10 - 12:10 PT **ROUNDTABLE 2**

Evaluating the benefits of in-house clinical development and operations

- Clinical research conducted by CROs has become a "business as usual" paradigm in drug development
- Clinical trials conducted by CROs can be costly and exceed timelines, and generally require the sponsor to expend additional cost to oversee the CRO
- Companies that in-source clinical trial execution like TRACON, Seagen and Beigene realize significant cost and time savings. TRACON has developed a partnering model that offers the benefits of in-source clinical trials to partners wishing to streamline drug development

Charles Theuer
Chief Executive Officer
TRACON Pharmaceuticals

ABOUT THE SPEAKER
Dr. Theuer is President and Chief Executive Officer of TRACON Pharmaceuticals. From 2004 to 2006, Dr. Theuer was Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc. where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Dr. Theuer was the Director of Clinical Oncology at Pfizer, where he led the clinical development of Sutent® in kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals and the National Cancer Institute where he was involved in the development of multiple small molecules and monoclonal antibody therapies.

12:10 - 13:10 PT **NETWORKING LUNCH**

13:10 - 13:40 PT **AFTERNOON KEYNOTE PRESENTATION**
See Page 6

13:40 - 14:40 PT **ROUNDTABLE 3**

Challenges and opportunities in Oncology Clinical development

- Dose optimization has been lacking in Oncology clinical development until the recent introduction of FDA's Project Optimus. How can we efficiently generate data to guide dose optimization while minimizing patient exposure to inactive doses of compounds in development?
- The evolving designs of early phase oncology clinical trials to maximize a drug's potential
- Translating early efficacy data to success in pivotal trials
- Challenges and opportunities for indication selection for individual drugs in oncology clinical development
- Monotherapy, combination treatment and confidence in contribution of components

Joanne Sloan Lancaster
Vice President, Program Team Leadership
NGM Bio

ABOUT THE SPEAKER
Dr. Sloan Lancaster brings over 25 years of drug development experience, focusing on autoimmune and immune oncology early clinical development. She is currently VP Program Team Leadership, Oncology Clinical Development, at NGM. Joanne began her career at Eli Lilly in several roles of increasing leadership, including Therapeutic Antibody Discovery, early clinical development within Chorus Lilly, and Head of Exploratory Medicine and Clinical Pharmacology, Immunology and Oncology. Joanne was most recently Vice President, Program Team Leadership at Calico prior to joining NGM. Joanne received her BSc in Immunology from the University of Glasgow, her PhD in Immunology from Washington University St. Louis, and post-doctoral training at the NIH.

14:40 -15:50 PT **REFRESHMENT BREAK & NETWORKING / 1-1 MEETINGS**

15:50 - 16:20 PT **PANEL DISCUSSION**
See Page 6

16:20 -17:20 PT **DRINKS & CANAPES RECEPTION**

new for 2023

Event Day

TRACK 6

Investment, Private Equity & Venture Capital Partnerships

Bringing together Managing Partners & C-level executives from investment firms supporting innovation in the clinical trial process, strategies from pharma companies and corporate arms with a vested interest in driving this innovation. It comes with the purpose of identifying and collaborating with potential drug development partners whilst addressing industry challenges in this area

09:00 - 10:00 PT ROUNDTABLE 1

Creative solutions for funding early stage oncology innovation

- The state of VC and PE markets after the 2019-2022 rollercoaster ride
- Accessibility of traditional funding sources
- Licensing and partnering deals in today's environment
- Creative dealmaking strategies in a capital-constraint environment

Will Robberts
President
LIPAC Oncology

ABOUT THE SPEAKER
Speaker TBC

11:10 - 12:10 PT ROUNDTABLE 2

Best practices and success factors to raising funds and building an innovative biotech company. Which assets and technologies investors will be looking for in your intellectual property portfolio

- Funding assets/innovative molecular targets vs. new modalities and technologies addressing limitation of better-known molecular targets in 2023
- Company growth stage or lead asset development phase investments to be preferably made in 2023
- IRA impact on investment strategy moving forward. Recommendations to companies fundraising in 2023
- Best practices and recommendations with respect to data package, timing, and most successful path to approaching investor community
- Top 3 success factors you've observed with the winners in your respective portfolios in challenging fundraising environments (recent and historic examples)

Anna Vardanyan
Vice President, Business Development
Inmagene Biopharma

ABOUT THE SPEAKER
Physician-Scientist, Dr. Anna Vardanyan has built a career founded on passion for life science innovation and development of new therapies for patients in need. She currently holds the position of Vice President, Business Development at Inmagene Therapeutics after her stint as Executive Director of Business Development at Turning Point/BMS. Dr. Vardanyan has 15+ years of pharma and biotech experience and held various positions of increasing responsibility in R&D and Business Development at Genzyme, Sanofi, Everest Medicines, Turning Point Therapeutics and BMS. She has extensive experience managing cross border transactions, including US, EU, and Asia, overseeing the full lifecycle of BD opportunities, and proven record of leadership spanning a broad range of therapeutic areas.

13:40 - 14:40 PT ROUNDTABLE 3

An insight into the investor mindset: How to identify, analyse and mitigate risk in a competitive market.

- Where do you think the next hot spots will be in oncology? (next gen immuno-oncology, new modalities like gene editing and RNA based therapies, the next breakthrough small molecule targets, or others?)
- How do you balance the various risk factors in your overall assessment of an asset, e.g. market timing (FIC vs fast follower), market size (broad vs niche), development stage (preclinical vs early vs late stage clinical)?
- What are your most trusted and reliable channels and processes to identify assets? Partnership meetings, personal contacts, third party advisory firms, etc.?
- How can you analyze each potential investor to demonstrate your fit to increase the likelihood of a response and an investment
- How can you use articulation of key milestones - scientific, business or funding - to help mitigate the risk for investors
- What factors in your company or portfolio can be used to convince an investor that you are a better investment

Stan Jin
Co-founder and Chief Executive Officer
Molecular Axiom

Jack Florio
Managing Director
Weild & Co

ABOUT THE SPEAKERS
Stan Jin is a scientist-turned-serial entrepreneur. Currently he is co-founder and CEO of Molecular Axiom, a cutting edge RNA based therapeutics company. Prior to that, he co-founded Fronthera Pharmaceuticals in 2015, which was acquired by Foresite Capital for $180M in March, 2021. A seasoned drug hunter, Stan has filed >60 patent applications and contributed to the discovery of a number of clinical programs in his 20 years of pharma/biotech industry experience. .

Jack Florio is a life sciences executive with 50 years of experience across the full range of pharma / biotech companies spanning early-stage company formation through capital formation, operations, and exits. This gives him a unique view of strategy and tactics across the life cycle of many companies.Jack is a Managing Director with Weild & Co. where he works on advisory, capital formation and M&A deals across the sector. He is also an angel investor with NuFund Venture Group and a Partner with Deallus, a global life sciences consultancy.

ONCOLOGY

STRATEGY MEETING WEST COAST USA 2023

10th May 2023, Wednesday Hard Rock Hotel San Diego

Hotel & Venue

Hard Rock HOTEL SAN DIEGO

Hard Rock Hotel San Diego

You're the main act in San Diego. At Hard Rock Hotel, we immerse you in our musical amenities, world-class service, and intoxicating location in

HOTEL DISCOUNTED RATE: **$299 USD** only

BOOK NOW!
We only have limited rooms available!

Hotel Details > Map & Directions >




OUR FACE-TO-FACE MEETING IN MAY 2023

Strategy Meeting San Diego, Boston & Princeton USA

MAY 2023

San Diego - US West Coast
08th - Drug Discovery Biology Strategy Meeting
09th - Medicinal Chemistry Strategy Meeting
10th - Oncology Strategy Meeting
11th - Clinical Operations Strategy Meeting

MAY 2023

Boston/Cambridge MA - US East Coast
17th - Regulatory Affairs Strategy Meeting
18th - Chemistry, Manufacturing and Controls Strategy Meeting

MAY 2023

Princeton New Jersey - US East Coast
23rd - Drug Discovery Biology Strategy Meeting
24th - Medicinal Chemistry Strategy Meeting
25th - Clinical Operations Strategy Meeting

Visit us on our website to know more about our meetings
www.proventainternational.com